BP
BPMUF.US Basilea Pharmaceutica AG
- Market cap
- USD 1.04B
- P/E
- 16.6x
- P/B
- 5.26x
- ROE
- 68.9%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is BPMUF.US undervalued?
Graham numberBPMUF.US trades 97.1% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Basilea Pharmaceutica AG fundamental analysis
No fundamental analysis for Basilea Pharmaceutica AG yet.
Basilea Pharmaceutica AG stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Basilea Pharmaceutica AG
Basilea Pharmaceutica AG is a Swiss commercial-stage biotech company focused on developing and commercializing treatments for severe bacterial and fungal infections. The company offers Cresemba (isavuconazole), an intravenous and oral antifungal for the treatment of invasive aspergillosis and mucormycosis; and Zevtera (ceftobiprole), an antibiotic for the treatment of pneumonia, Staphylococcus aureus bacteremia (SAB), acute bacterial skin, community-acquired bacterial pneumo…
Full company profileBasilea Pharmaceutica AG financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Basilea Pharmaceutica AG annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 66.0M | 102M | 133M | 134M | 128M | 148M | 148M | 158M | 209M | 233M | 473M |
| Gross Profit | 60.6M | 92.5M | 112M | 116M | 104M | 124M | 123M | 131M | 170M | 193M | 412M |
| Operating Income | -43.9M | -14.1M | -24.1M | -17.2M | -8.22M | 1.19M | 18.5M | 19.2M | 61.2M | 51.6M | 126M |
| EBITDA | -41.6M | -10.4M | -22.2M | -14.3M | -5.89M | 3.76M | 21.9M | 23.2M | 66.3M | 51.0M | 136M |
| Net Income | -51.3M | -19.4M | -31.4M | -22.4M | -14.7M | -6.83M | 12.1M | 10.5M | 77.6M | 40.2M | 111M |
| EPS | -5.07 | -1.79 | -2.89 | -2.08 | -1.43 | -0.58 | 1.02 | 0.86 | 5.60 | 3.14 | 8.05 |
| Balance Sheet | |||||||||||
| Total Assets | 328M | 351M | 282M | 221M | 230M | 247M | 221M | 173M | 258M | 282M | 296M |
| Total Liabilities | 363M | 393M | 348M | 314M | 332M | 306M | 266M | 183M | 177M | 154M | 135M |
| Shareholders' Equity | -35.0M | -41.4M | -66.7M | -93.0M | -102M | -58.6M | -45.0M | -10.0M | 81.0M | 128M | 161M |
| Cash & Short-term Investments | 239M | 261M | 224M | 129M | 162M | 149M | 84.7M | 59.9M | 121M | 162M | 175M |
| Total Debt | 195M | 196M | 197M | 198M | 242M | 219M | 187M | 129M | 112M | 89.2M | 83.0M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -75.0M | 19.0M | -79.2M | -63.8M | -54.1M | -32.0M | 7.06M | 14.2M | 74.4M | 62.1M | 75.5M |
| Capital Expenditure | 431K | 945K | 609K | 404K | 2.27M | 860K | 3.30M | 1.03M | 1.79M | 2.62M | 1.63M |
| Free Cash Flow | -75.4M | 18.1M | -79.8M | -64.2M | -56.4M | -32.9M | 3.75M | 13.2M | 72.6M | 59.5M | 73.8M |
| Ratios | |||||||||||
| ROE | - | - | - | - | - | - | - | - | 95.8% | 31.4% | 68.9% |
| ROA | -15.6% | -5.5% | -11.1% | -10.1% | -6.4% | -2.8% | 5.5% | 6.0% | 30.1% | 14.3% | 37.5% |
| Net Profit Margin | -77.7% | -19.1% | -23.7% | -16.7% | -11.5% | -4.6% | 8.2% | 6.6% | 37.2% | 17.3% | 23.5% |
| Debt to Equity | - | - | - | - | - | - | - | - | 1.38x | 0.70x | 0.51x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Basilea Pharmaceutica AG dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | USD 23.2M | 1.99 | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Basilea Pharmaceutica AG
- Insiders 0.62%
- Institutions 30.69%
- Public & others 68.69%
- Shares outstanding 12.4M
- Free float 11.3M
Basilea Pharmaceutica AG company profile
- Company name
- Basilea Pharmaceutica AG
- Ticker
- BPMUF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 200
- Fiscal year end
- December
- Address
- Hegenheimermattweg 167b, Allschwil, Switzerland, 4123
- Phone
- 41 61 606 11 11
- Website
- basilea.com
About Basilea Pharmaceutica AG
Basilea Pharmaceutica AG is a Swiss commercial-stage biotech company focused on developing and commercializing treatments for severe bacterial and fungal infections. The company offers Cresemba (isavuconazole), an intravenous and oral antifungal for the treatment of invasive aspergillosis and mucormycosis; and Zevtera (ceftobiprole), an antibiotic for the treatment of pneumonia, Staphylococcus aureus bacteremia (SAB), acute bacterial skin, community-acquired bacterial pneumonia, and skin structure infections (ABSSSI). The company also has a clinical-stage pipeline of anti-infective assets that include fosmanogepix, a broad-spectrum antifungal in phase 3 development for invasive mold infections; ceftibuten-ledaborbactam etzadroxil, a phase 3 - ready oral antibiotic for the treatment of complicated urinary tract infections (cUTI); BAL2062, a candidate for invasive aspergillosis currently advancing toward phase 2 clinical development; and BAL2420, a preclinical-stage antibiotic targeting severe enterobacteriaceae infections. The company has a strategic collaboration with Prokaryotics, Inc for the development of broad-spectrum antifungal targeting drug-resistant pathogens through a differentiated mechanism of action; and Phare Bio, a biotech social venture to leverage generative artificial intelligence (AI) to transform antibiotic discovery. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Allschwil, Switzerland.
Basilea Pharmaceutica AG management
10- Mr. David VeitchChief Executive Officer · born 1965
- Mr. Adesh KaulChief Financial Officer · born 1974
- Dr. Gerrit Hauck Ph.D.Chief Technology Officer · born 1964
- Dr. Laurenz Kellenberger Ph.D.Chief Scientific Officer · born 1967
- Dr. Marc Engelhardt M.D.Chief Medical Officer · born 1964
- Dr. Peer Nils Schroder Ph.D.Head of Corporate Communications & Investor Relations
- Mr. Damian HellerGeneral Counsel & Corporate Secretary · born 1966
- Mr. Andreas KuminHead of Corporate Development
- Ms. Ursula EberhardtHead of Global Human Resources · born 1962
- Mr. Mark Jones Ph.D.Head of Global Affairs · born 1967